Regional Database for Collecting Clinical-biological and Imaging Data "Secondary Bone Oncology and Bone Localizations of Hematologic Diseases"

Not yet recruiting

• Conditions: Bone Metastases

• Registration Number: NCT05495802
• Lead Sponsor: University Hospital, Lille

Brief Summary

Improving the effectiveness of cancer treatments makes it possible to lengthen patient survival. It is therefore important to ensure that the quality of life is also maintained by reducing pain and handicap.

Some cancers tend to spread to the bone. The bone locations of cancer can weaken the bone and lead to complications such as fractures, pain, or compression of neurological structures.

To avoid such complications, weekly multidisciplinary meetings (MM) bring together specialists (oncologists, rheumatologists, cancer surgeons, radiologists, radiotherapists, etc.) to discuss the files of patients with bone lesions from cancer. They offer specific treatments adapted to each patient to treat or reduce the risk of complications. The OOSLOH study aims to collect clinical, biological, and imaging data from patients for whom a discussion took place in bone dedicated MM. Based on these data, epidemiological studies could be carried out to better understand the clinical factors leading cancer to colonize bone. But also to determine the factors making it possible to prevent or better treat bone complications and improve the quality of life of patients. This study does not require any examinations or additional visits to the patient

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-08-03
• Status Verified: 2022-08
• Study First Submitted QC: 2022-08-08
• Last Update Submitted: 2022-08-08
• Study First Posted: 2022-08-10
• Last Update Posted: 2022-08-10
• Study Start: 2022-12
• Primary Completion: 2032-11
• Study Completion: 2032-12

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 5000

Inclusion Criteria

• Patient aged 18 or over,
• Patient whose file is presented to the OOSLOH MM and who has not objected to the use of his non-nominative clinical, biological and imaging data
• Social insured patient

Exclusion Criteria

• Patient who died before presentation to OOSLOH MM,
• Minor patient,
• Patient objecting to the use of their data for research purposes,
• Patient unable to express his right to object to his participation in the study.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Percentage of alive patients	through study completion, an average of 10 years

Secondary Outcome Measures

Name	Time	Method
Epidemiological datas	At the first presentation of patient's file to the MM, on average every week
Percentage of patients without bone disease recurrence	within one year after the multidisciplinary meeting
Time to bone disease recurrence	through study completion, an average of 10 years
Number of bone recurrence Number of bone recurrence	At each presentation of the patient file's to the MM,on average every week